Single Isothermal Assay for Multi-Site Mutation Detection of Rifampicin Resistance in Mycobacterium tuberculosis
Pathogens · 2026-02-08 · 15 (2) · 187
DOI: 10.3390/pathogens15020187 ↗At a glance
Journal article in Pathogens, published online on 2026-02-08. Written by Nidhi Nandu and 2 co-authors. Institution: Revvity, Inc., 77 4th Ave, Waltham, MA 02451, USA. Major MEDLINE topics: Mycobacterium tuberculosis, Rifampin, Drug Resistance, Bacterial, Nucleic Acid Amplification Techniques. Cited 1 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0). Funded by: Revvity (United States), Revvity, Inc..
Abstract (original language)
Antimicrobial drug resistance is an escalating global health burden, often driven by multiple genetic changes within key resistance-associated genes. Achieving multiplex capability of mutation detection while maintaining simplicity and affordability is critical, particularly in point-of-care and resource-limited settings. Here, we introduce a strategy for multi-site mutation detection using single isothermal amplification of a nucleic acid fragment spanning multiple mutations in the rifampicin resistance-determining region (RRDR) of the rpoB gene, encompassing codons 516 and 526 in Mycobacterium tuberculosis. This unified design eliminates competition among targets amplified by multiple primer sets. Site-specific hybridization probes enable accurate discrimination between wild-type and mutant sequences, while an integrated self-calibration probe provides normalization to mitigate variability from sample concentration and sample matrix interference. To validate this approach, we applied it to detect rifampicin (RIF) resistance mutations at codons 516 and 526 of the rpoB gene in Mycobacterium tuberculosis, which are two key targets for molecular diagnostics and surveillance. Using 42 artificial DNA fragments, which included both wild-types and mutants with single- or two-site mutations, the assay achieved 100% accuracy in discriminating between wild-type and mutant sequences for codon 516. On the other hand, sequences harboring mutations at codon 526 were identified with 100% accuracy, compared to 94% accuracy for wild-type sequences. Overall, the system achieved a 100% positive percent agreement (PPA) for drug-resistance sequences and 97% negative percent agreement (NPA) for drug-sensitive sequences based on these 42 samples. These findings suggest that this method has the potential to provide a reliable framework for multi-site mutation detection.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Revvity, Inc., 77 4th Ave, Waltham, MA 02451, USA.
ORCID profiles: Nidhi Nandu, Michael Miller, Zhi-Xiang Lu
Funding
- Revvity (United States)
- Revvity, Inc.
Cite
APA
Nandu, N., Miller, M., & Lu, Z. X. (2026). Single Isothermal Assay for Multi-Site Mutation Detection of Rifampicin Resistance in Mycobacterium tuberculosis. Pathogens, 15(2), 187. https://doi.org/10.3390/pathogens15020187
Vancouver
Nandu N, Miller M, Lu ZX. Single Isothermal Assay for Multi-Site Mutation Detection of Rifampicin Resistance in Mycobacterium tuberculosis. Pathogens. 2026;15(2):187. doi:10.3390/pathogens15020187
BibTeX
@article{Nandu2026,
author = {Nandu, Nidhi and Miller, Michael and Lu, Zhi-Xiang},
title = {Single Isothermal Assay for Multi-Site Mutation Detection of Rifampicin Resistance in Mycobacterium tuberculosis},
journal = {Pathogens},
year = {2026},
volume = {15},
number = {2},
pages = {187},
doi = {10.3390/pathogens15020187}
}
EUVIMED